12:00 AM
Nov 19, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Status

MK-5172: Phase II started

Merck began an open-label Phase II trial to evaluate 100 mg oral MK-5172 once daily in combination with ribavirin for 12 or 24 weeks in about 24 patients. Merck markets ...

Read the full 133 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >